Affinity Asset Advisors acquired a new position in Praxis Precision Medicines, purchasing 185,000 shares worth an estimated $54.53 million on February 13, 2026. The stake now represents 3.11% of the fund’s 13F reportable assets, with top fund holdings including APGE, INSM, ABVX, VTYX, and XENE.

Shares of Praxis Precision Medicines were valued at $317.25 on February 13, 2026, marking a 266.1% increase over the past year, significantly outperforming the S&P 500 by 254.29 percentage points. The company focuses on developing clinical-stage therapies for central nervous system disorders, with lead candidates targeting various neurological and psychiatric conditions.

Praxis Precision Medicines recently announced the submission of new drug applications for ulixacaltamide and relutrigine, both receiving Breakthrough Therapy Designation. With pro forma cash and investments of around $956 million, the company aims to fund operations into 2028. Research and development expenses rose to $65.8 million in the third quarter, reflecting the firm’s focus on late-stage programs.

Investors considering Praxis Precision Medicines should note that the stock was not included in the Motley Fool Stock Advisor’s list of the 10 best stocks to buy now. The Stock Advisor’s total average return is 884%, substantially outperforming the S&P 500, with a focus on community-driven investment strategies.

Read more at Yahoo Finance: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress